Evidence map›Paper›PMID 40208447›Full record

ArticleInternational urology and nephrology2025

Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma.

Yuki Nemoto, Takanori Endo, Hogara Segawa, Kazutaka Nakamura, Koichi Nishimura, Toshihide Horiuchi, Daisuke Toki, Hirohito Kobayashi, Toshio Takagi, Tsunenori Kondo

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuki NemotoDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Takanori EndoDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Hogara SegawaDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Kazutaka NakamuraDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Koichi NishimuraDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Toshihide HoriuchiDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Daisuke TokiDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Hirohito KobayashiDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan.
Tsunenori KondoDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, Japan. kondo.tsunenori@twmu.ac.jp.ORCID http://orcid.org/0000-0002-5146-656X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo clarify the efficacy and safety profile of nivolumab plus cabozantinib combination therapy in advanced renal cell carcinoma patients older than 80 years.

methodsWe retrospectively evaluated 42 patients with advanced renal cell carcinoma treated with nivolumab plus cabozantinib as the first-line therapy at our institution. The patients were categorized according to age as those aged ≥ 80 years and those aged < 80 years. Efficacy was analysed by comparing the progression-free survival, overall survival, objective response rate, and disease control rate between the two groups. Safety was assessed by comparing the incidence of adverse events.

resultsTen patients (31%) were classified as age ≥ 80 group. No significant differences were observed in the progression-free survival (p = 0.682), the overall survival (p = 0.627), objective response rate (p = 0.195), and disease control rate (p = 0.070) between the two groups. There was no significant difference in the incidence of all grades of adverse events(p = 1.000), but there was a trend toward a higher incidence of grade 3 or higher adverse events in the group of patients aged < 80 years (p = 0.066).

conclusionsThe efficacy and safety of nivolumab plus cabozantinib combination therapy were comparable between the patients aged ≥ 80 years and those aged < 80 years. Thus, chronological age alone is not a contraindication for nivolumab plus cabozantinib combination therapy for advanced renal cell carcinoma.

Indexed as

AnilidesAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsNivolumabPyridinesAgedAged, 80 and overAge FactorsFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAnilidesAntineoplastic Agents, ImmunologicalcabozantinibNivolumabPyridinesImmunotherapyKidney cancerProgrammed cell death protein 1Renal cancerTyrosine kinase inhibitor

Identifiers

PMID40208447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.